Simultaneously, in vivo experiments showed that the tumorigenic ability of bladder cancer cells in vivo was diminished by treatment with sh-SNHG1 alone and elevated by treatment with miR-9-3p inhibitor alone, which was neutralized by co-treatment with sh-SNHG1 and miR-9-3p antagomir (Figure 6F,G). The gene discussed is SNHG1; the disease is urinary bladder cancer.